Cart
sales@molnova.com
CCT128930
CAS No. 885499-61-6
CCT128930 ( CCT 128930;CCT-128930 )
Catalog No. M16409 CAS No. 885499-61-6
CCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 59 | In Stock |
|
| 5MG | 104 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 368 | In Stock |
|
| 50MG | 536 | In Stock |
|
| 100MG | 779 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCCT128930
-
NoteResearch use only, not for human use.
-
Brief DescriptionCCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2).
-
DescriptionCCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2), 28-fold selectivity over the closely related PKA; also exhibits 20-fold selectivity over p70S6K (IC50=120 nM); shows growth inhibition for U87MG human glioblastoma cells (IC50=6.3 uM), for LNCaP human prostate cancer cells (IC50=0.35 uM), and for PC3 human prostate cancer cells (IC50=1.9 uM) consistent with AKT pathway blockade; blocks the phosphorylation of several downstream AKT biomarkers in U87MG tumor xenografts, indicating AKT inhibition in vivo; demonstrates antitumor activity in U87MG and HER2-positive, PIK3CA-mutant BT474 human breast cancer xenografts.
-
SynonymsCCT 128930;CCT-128930
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetAkt
-
RecptorAkt2 , p70 S6K , PKA
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number885499-61-6
-
Formula Weight341.80
-
Molecular FormulaC18H20ClN5
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESNC1(CC2=CC=C(Cl)C=C2)CCN(C3=C4C(NC=C4)=NC=N3)CC1
-
Chemical Name4-Piperidinamine, 4-[(4-chlorophenyl)methyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Caldwell JJ, et al. J Med Chem. 2008 Apr 10;51(7):2147-57.
2. Yap TA, et al. Mol Cancer Ther. 2011 Feb;10(2):360-71.
3. Yap TA, et al. Clin Cancer Res. 2012 Jul 15;18(14):3912-23.
2. Yap TA, et al. Mol Cancer Ther. 2011 Feb;10(2):360-71.
3. Yap TA, et al. Clin Cancer Res. 2012 Jul 15;18(14):3912-23.
molnova catalog
related products
-
I-CBP112 hydrochlori...
I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors. I-CBP112 (1 mM) has little activity against other bromodomains.
-
AT7867 dihydrochlori...
AT7867 is a potent, ATP-competitive, orally available dual Akt and p70S6K inhibitor with Ki of 17-85 nM.
-
NSC 86429
SU-4312, also known as DMBI, is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively).
